DNLI

Denali Therapeutics Inc

DNLI.US denalitherapeutics.com + Research + Basket
CIK 0001714899
Employees 503
Phone 650 866 8547
Fiscal year end December
IPO Dec 08, 2017
Address 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
20.17
+0.45 (+2.28%)
USD · NASDAQ
52-week range
13.75
27.30
Trading at 47% of the 52-week range
Market Cap
3.35B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
6.49
Div. Yield
N/A
% Institutions
101.22%
% Insiders
4.61%

1 Year

+32.4%

3 Year

-5.0%

10 Year

-8.1%
Description

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Actions

Add an action for DNLI.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Ryan J. Watts Ph.D. Co-Founder, President, CEO & Director 1976
Dr. Alexander O. Schuth M.D., Ph.D. Co-Founder, CFO, COO & Secretary 1973
Dr. Dana Andersen Chief Technical and Manufacturing Officer NA
Mr. Joe Lewcock Ph.D. Chief Scientific Officer NA
Mr. Chris Walsh J.D. General Counsel NA
Ms. Cindy Dunkle Chief People Officer NA
Ms. Katie Peng M.B.A. Chief Commercial Officer 1971
Mr. Peter Chin M.D. Acting Chief Medical Officer & Head of Development 1968

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Jan 06, 2026 Alexander O Schuth N/A Sale 17.22K $16.50 $284.10K SEC
Jan 06, 2026 Ryan J Watts N/A Sale 35.20K $16.50 $580.77K SEC
Aug 13, 2025 Carole Ho N/A Sale 806.00 $14.64 $11.80K SEC
Aug 12, 2025 Alexander O Schuth N/A Sale 2.94K $13.58 $39.88K SEC
Aug 12, 2025 Carole Ho N/A Sale 2.94K $13.58 $39.88K SEC
Jul 09, 2025 Ryan J Watts N/A Sale 495.28K $15.00 $7.43M SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
T. Rowe Price Investment Management,Inc. 16.18M Jun 30, 2026 10.12% $0.27 89.91%
BlackRock Inc 14.03M Jun 30, 2026 8.77% $0.01 7.61%
Baillie Gifford & Co Limited. 11.96M Jun 30, 2026 7.48% $0.28 -0.88%
State Street Corp 7.05M Jun 30, 2026 4.41% $0.01 12.39%
Temasek Holdings Ltd. 7.01M Jun 30, 2026 4.39% $0.48 0.00%
Vanguard Portfolio Management, LLC 6.48M Jun 30, 2026 4.05% $0.01 5.83%
Vanguard Capital Management, LLC 6.28M Jun 30, 2026 3.93% $0.00 2.08%
FMR Inc 4.54M Jun 30, 2026 2.84% $0.01 -0.86%
The Goldman Sachs Group Inc 4.16M Jun 30, 2026 2.60% $0.01 -5.70%
Geode Capital Management, LLC 3.97M Jun 30, 2026 2.49% $0.01 6.61%
Holocene Advisors, LP 3.91M Jun 30, 2026 2.44% $0.23 22.21%
Baker Bros Advisors LP 3.73M Jun 30, 2026 2.34% $0.48 0.07%
UBS Asset Mgmt Americas Inc 3.16M Jun 30, 2026 1.98% $0.01 -28.66%
T. Rowe Price Associates, Inc. 3.14M Jun 30, 2026 1.96% $0.01 27.27%
UBS Group AG 3.12M Jun 30, 2026 1.95% $0.01 21.36%
AllianceBernstein L.P. 2.98M Jun 30, 2026 1.87% $0.02 3.15%
Dimensional Fund Advisors, Inc. 2.86M Jun 30, 2026 1.79% $0.01 6.26%
NORGES BANK 2.82M Jun 30, 2026 1.77% $0.01 -44.83%
Pictet Asset Manangement SA 2.79M Jun 30, 2026 1.75% $0.07 9.08%
Capital Research Global Investors 2.57M Jun 30, 2026 1.61% $0.01 2.04%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Scottish Mortgage Ord 7.04M 4.41% ▲ 0.00% Jul 31, 2026
2 T. Rowe Price Capital Appreciation 6.55M 4.10% ▲ 0.00% Sep 30, 2026
3 Vanguard MStar Total Stk Mkt Idx Invest 4.68M 2.93% ▲ 8.79% Sep 30, 2026
4 iShares Russell 2000 ETF 3.74M 2.34% ▼ 0.41% Oct 29, 2026
5 Vanguard Small Cap Index 3.24M 2.03% ▲ 4.44% Sep 30, 2026
6 State Street® SPDR® S&P® Biotech ETF 3.19M 2.00% ▼ 0.80% Oct 29, 2026
7 American Funds SMALLCAP World A 2.50M 1.56% ▲ 0.00% Sep 30, 2026
8 T. Rowe Price Small-Cap Stock 2.27M 1.42% ▼ 0.57% Sep 30, 2026
9 Vanguard US Growth Investor 2.27M 1.42% ▼ 25.26% Sep 30, 2026
10 Vanguard MStar Small Cap Growth Indx Inv 1.80M 1.13% ▲ 0.97% Sep 30, 2026

Financial Highlights

▼
Market Cap: $3.35B
EBITDA: $-526.06M
Book Value: $6.49
Earnings/Share: $-1.72
Profit Margin: 0.00%
Operating Margin: -3,601.30%
ROA (TTM): -29.15%
ROE (TTM): -54.93%
Revenue (TTM): $3.60M
Revenue/Share (TTM): $0.02
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -100.00%

Valuation Metrics

Enterprise Value: $2.44B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 159.85M
Shares Float: 155.10M
% Insiders: 4.61%
% Institutions: 101.22%
Shares Short: 15.48M
Shares Short (Prior Month): 15.46M
Short Ratio: 7.76
Short % Float: 10.21%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-11.18M
Gross Profit
subtotal
$-11.18M
SG&A
adjust
$-97.10M
R&D
adjust
$-418.78M
Other Operating Expense
adjust
$-28.28M
Operating Income
subtotal
$-555.34M
Other / Non-Operating Items
adjust
$42.80M
Net Income
subtotal
$-512.54M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about DNLI.US!